Laura Brass is a Managing Director at Novartis Venture Fund who focuses on seed and Series A investments. See sector focus and contact routes.
Laura Brass is a Managing Director at Novartis Venture Fund who focuses on seed and Series A investments in Pharmaceuticals and Biotechnology, typically with check sizes between $5.0M and $10.0M per round. Her firm’s distinctive thesis prioritizes novel therapeutics and platforms that address unmet clinical needs, featuring proprietary science and capital efficiency, with total investments per company potentially reaching $30M–$50M over their lifecycle. Notable portfolio companies where she serves as a board director include Alesta Therapeutics, Immunitas Therapeutics, Averna Therapeutics, and Annexon (which achieved an IPO).
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Basel.
Investors like Laura Brass · Full investor directory · Investor access · Company funding database